Walleye Capital
ADPT icon

Walleye Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Walleye Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-600
Closed -$4.58K – 3875
2022
Q4 		$4.58K Buy
+600
New +$4.67K ﹤0.01% 2864

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Walleye Capital's ADPT Position: Q1 2026 in Review

Walleye Capital sold out of Adaptive Biotechnologies (ADPT) in Q1 2026, closing a stake of 95,324 shares — an estimated $1.55M sold.

Walleye Capital first reported a position in ADPT in Q3 2020 and held it in 7 quarters. The position peaked at $1.55M in Q4 2025. 295 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • Walleye Capital reported no remaining Adaptive Biotechnologies position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 95,324 Adaptive Biotechnologies shares in Q1 2026, an estimated $1.55M.
  • Walleye Capital first reported a position in Adaptive Biotechnologies in Q3 2020 and held it in 7 quarters.
  • Walleye Capital's Adaptive Biotechnologies position peaked at $1.55M in Q4 2025.
  • 295 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.